secwatch.observer — SEC 8-K summary
======================================

Issuer:     TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
CIK:        0000818686
Form:       8-K
Filed at:   2023-03-03T23:59:59+00:00
Accession:  0001193125-23-058966
Event type: debt
Sentiment:  neutral
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Teva prices $2.49B sustainability-linked senior notes; upsizes tender offer to $2.5B
--------------------------------------------------------------------------------

- Priced €800M 7.375% notes due 2029, €500M 7.875% notes due 2031, $600M 7.875% notes due 2029, $500M 8.125% notes due 2031.
- Upsized offering from $2.06B to $2.49B equivalent; increased tender offer max from $2.25B to $2.5B.
- Proceeds to fund cash tender offers for six series of existing senior notes due 2023-2026 and repay debt.
- Second sustainability-linked bond issuance; targets include improving medicine access in LMICs and reducing GHG emissions.
- Settlement expected March 9, 2023; notes are unsecured senior obligations guaranteed by Teva.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/818686/000119312523058966/0001193125-23-058966-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/818686/000119312523058966/d422149d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-058966

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer